Multimorbidity and polypharmacy: Which betablocker to use in relation to the pharmacokinetic profile and interaction potential

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 2, 2010, Pages 57-63

  Wehling, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Betablockers; Interactions; Multimorbidity; Polypharmacy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; AMLODIPINE; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CARVEDILOL; CELIPROLOL; CIMETIDINE; CODEINE; CYTOCHROME P450 2D6; DRONEDARONE; DRUG METABOLIZING ENZYME; ENCAINIDE; ESMOLOL; FLECAINIDE; FLUOXETINE; METOPROLOL; NEBIVOLOL; NEUROLEPTIC AGENT; PAROXETINE; PROPAFENONE; PROTEINASE INHIBITOR; RIFAMPICIN; SERTRALINE; SOTALOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; DRUG TOLERANCE; DRUG TRANSPORT; DRUG USE; ENZYME POLYMORPHISM; GENE INTERACTION; GENETIC VARIABILITY; HUMAN; KIDNEY FUNCTION; POLYPHARMACY; REVIEW; STEREOCHEMISTRY; URINARY EXCRETION;

EID: 77249118835     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296249     Document Type: Review

References (51)

1. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287:337-44.
2. Lazarou J, Pomeranz BH, Corey PN Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-5.
3. World Population Prospects: the 2008 Revision Population Database, medium variant. c 2009 - [cited 26 November 2009]. Available from: http://esa.un.org/unpp/
4. Glaeske G, Schicktanz C, Janhsen K. GEK-Arzneimittel-Report 2008, Schriftenreihe zur Gesundheitsanalyse. Band 61. St. Augustin (Germany): Asgard-Verlag; 2008.
5. Franciosa JA. Beta-adrenergic blocking agents: past, present, and future perspectives. Coron Artery Dis. 1999;10: 369-76.
6. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334: 1349-55.
7. Northcote RJ, Ballantyne D. Beta-adrenoceptor blockade and intrinsic sympathomimetic activity-relevance in the treatment of ischaemic heart disease. Scott Med J. 1993; 30:205-15.
8. Christ M, Wehling M. Betablocking agents in patients with coronary artery disease and myocardial infarction. In: Böhm M, Laragh J, Zehender P, editors. From hypertension to heart failure. Berlin: Springer; 1998. p. 90-129.
9. Wagner F, Kalusche D, Trenk D, Jähnchen E, Roskamm H. Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol. 1987;24:213-20.
10. Walley T, Pirmohamed M, Proudlove C, Maxwell D. Interaction of metoprolol and fluoxetine. Lancet . 1993; 341(8850):967-8.
11. Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol. 2008;64:275-82.
12. Brodde OE, Kroemer HK. Drug-drug interactions of betaadrenoceptor blockers. Arzneimittelforschung. 2003;53(12): 814-22.
13. Scheen AJ. Pharma-clinics medication of the month. Nebivolol (Nobiten). Rev Med Liege. 2001;56:788-91.
14. Reynolds RD, Gorczynski RJ, Quon CY. Pharmacology and pharmacokinetics of esmolol. J Clin Pharmacol. 1986;26 Suppl A:A3-A14.
15. Zhou HH, Wood AJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther. 1995;57: 518-24.
16. Meyer UA. Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proc Natl Acad Sci U S A. 1994;91:1983-4.
17. Bertilsson L, Dahl ML, Tybring G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand. 1997;391 Suppl:14-21.
18. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and Psychopharmacotherapy. J Clin Pharm Ther. 2000;25:197-220.
19. Lewis DF,Watson E, Lake BG. Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. Mutat Res. 1998;410:245-70.
20. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype-a major determinant of metoprolol metabolism and response. N Engl J Med. 1982; 307:1558-60.
21. Wuttke H, Rau T, Heide R, Bergmann K, Bohm M, Weil J, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther. 2002;72:429-37.
22. Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N , et al. Effect of CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics. 2002; 12:465-72.
23. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther. 2004;76:536-44.
24. Fux R, Morike K, Prohmer AM, Delabar U, Schwab M, Schaeffeler E, et al . Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther. 2005;78:378-87.
25. Shin J, Johnson JA. Pharmacogenetics of betablockers. Pharmacotherapy . 2007; 27:874-87.
26. Damy T, Pousset F, Caplain H, Hulot JS, Lechat P. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol. 2004;18:113-23.
27. Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol. 2008;64:1163-73.
28. Horikiri Y, Suzuki T, Mizobe M. Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63:1097-108.
29. Kirch W, Rose I, Klingmann I, Pabst J, Ohnhaus EE. Interaction of bisoprolol with cimetidine and rifampicin. Eur J Clin Pharmacol. 1986;31:59-62.
30. Fachinfo Service [Internet]. "Fachinformation" Concor®; c 2009 - [updated July 2008; cited 26 November 2009]. Available from: http://www.fachinfo.de/viewFI?FINR= 003991&RL= Concor%26reg%3B%205%26nbsp%3Bmg/-10% 26nbsp%3Bmg%20Filmtabletten.
31. Nozawa T, Taguchi M, Tahara K, Hashimoto Y, Igarashi N, Nonomura M, et al. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol. 2005;46:713-20.
32. Huang JD, Chuang SK, Cheng CL, Lai ML. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clin Pharmacol Ther. 1999;65: 402-7.
33. Taguchi M, Nozawa T, Kameyama T, Inoue H, Takesono C, Mizukami A, et al. Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. Eur J Clin Pharmacol. 2003;59:385-8.
34. POISE Study Group : Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, et al. Effects of extended-release metoprolol succinate in patients undergoing noncardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371:1839-1847.
35. Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. FundamClin Pharmacol. 2006;20:273-82.
36. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67-76.
37. McAinsh J, Holmes BF, Smith S, Hood D, Warren D. Atenolol kinetics in renal failure. Clin Pharmacol Ther. 1980;28: 302-9.
38. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serumcreatinine. Nephron. 1976;16:31-41.
39. Calis KA, Young LR. Clinical analysis of adverse drug reactions. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, editors. Principles of Clinical Pharmacology. San Diego: Academic Press; 2001.
40. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
41. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet . 2005;366(9489):895-906.
42. Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol. 2007;120:10-27.
43. Neutel JM, Smith DHG, Ram CV, Lefkowitz MP, Kazempour MK, Weber MW. Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. AmJ Cardiol. 1993;72:41-6.
44. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007;24:CD002003.
45. Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Platt R. Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice. Arch Intern Med. 2008;168:2415-21.
46. Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet. 1987;13:110-7.
47. McGavin JK, Keating GM.Bisoprolol: a review of its use in chronic heart failure. Drugs. 2002;62(18):2677-96.
48. Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol. 1986;8 Suppl 11:S16-20.
49. Campeanu A. The cardiac insufficiency talinolol study (CITAS) study design. Eur J Heart Fail. 2001;3:377-80.
50. Broncel M, Chojnowska-Jezierska J, Adamska-Dyniewska H. Bisoprolol in the treatment of hypertension in the elderly. J HumHypertens. 1998;12:643-4.
51. Düngen HD, Apostolovic S, Inkrot S, Tahirovic E, Krackhardt F, Pavlovic M, et al. Subproject Multicenter Trials in the Competence Network Heart Failure.Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol. 2008;97: 578-86.